Rosuvastatin in the Treatment of Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

September 24, 2021

Study Completion Date

September 24, 2021

Conditions
Rectal Cancer
Interventions
DRUG

Rosuvastatin

40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.

Trial Locations (1)

T2N 4N2

Tom Baker Cancer Centre, Calgary

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

lead

AHS Cancer Control Alberta

OTHER